BR0306925A - Formulações estabilizadas de adenovìrus - Google Patents

Formulações estabilizadas de adenovìrus

Info

Publication number
BR0306925A
BR0306925A BR0306925-7A BR0306925A BR0306925A BR 0306925 A BR0306925 A BR 0306925A BR 0306925 A BR0306925 A BR 0306925A BR 0306925 A BR0306925 A BR 0306925A
Authority
BR
Brazil
Prior art keywords
adenovirus
compositions
stabilized
formulations
adenovirus formulations
Prior art date
Application number
BR0306925-7A
Other languages
English (en)
Inventor
Erno Pungor
Elisabeth Lehmberg
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0306925A publication Critical patent/BR0306925A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Abstract

"FORMULAçõES ESTABILIZADAS DE ADENOVìRUS". A presente invenção refere-se a um método para estabilizar composições que compreendem vírus transportados pelo ar, particularmente o Adenovírus e, mais particularmente, o Adenovírus recombinante, mediante adição às composições de um detergente não-iónico, o qual compreende uma porção de alquila e uma porção de polietilenoglicol (PEG). São também divulgadas composições farmacêuticas e outras composições de Adenovírus, particularmente de Adenovírus recombinante, adequadas para métodos de terapia de gene, as quais compreendem os mencionados detergentes.
BR0306925-7A 2002-01-18 2003-01-15 Formulações estabilizadas de adenovìrus BR0306925A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34922202P 2002-01-18 2002-01-18
PCT/US2003/001055 WO2003061708A1 (en) 2002-01-18 2003-01-15 Stabilized formulations of adenovirus

Publications (1)

Publication Number Publication Date
BR0306925A true BR0306925A (pt) 2004-11-09

Family

ID=27613260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306925-7A BR0306925A (pt) 2002-01-18 2003-01-15 Formulações estabilizadas de adenovìrus

Country Status (18)

Country Link
US (1) US20030232018A1 (pt)
EP (1) EP1465664A1 (pt)
JP (1) JP2005515245A (pt)
KR (1) KR20040077878A (pt)
CN (1) CN1617745A (pt)
AR (1) AR038153A1 (pt)
BR (1) BR0306925A (pt)
CA (1) CA2469721A1 (pt)
IL (1) IL162404A0 (pt)
MX (1) MXPA04006995A (pt)
NO (1) NO20043418L (pt)
PE (1) PE20030851A1 (pt)
PL (1) PL371261A1 (pt)
RU (1) RU2004125283A (pt)
TW (1) TW200307750A (pt)
UY (1) UY27614A1 (pt)
WO (1) WO2003061708A1 (pt)
ZA (1) ZA200406547B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
SG190419A1 (en) 2010-12-02 2013-06-28 Oncolytics Biotech Inc Lyophilized viral formulations
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
US10294279B2 (en) 2013-06-17 2019-05-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2017060329A1 (en) * 2015-10-06 2017-04-13 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
SI3439672T1 (sl) 2016-04-05 2021-02-26 Janssen Vaccines & Prevention B.V. Stabiliziran topen pre-fuzijski F protein RSV za uporabo v profilaksi okužbe z RSV
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
EA039124B1 (ru) 2016-05-30 2021-12-08 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные f-белки rsv до слияния
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
BR112019015671A2 (pt) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv promotor potente e curto para expressão de genes heterológicos
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ269156A (en) * 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
CN100374551C (zh) * 1998-02-17 2008-03-12 先灵公司 含有病毒的组合物以及浓缩病毒制剂的方法
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1150712B1 (en) * 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
EP2420247A1 (en) * 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations

Also Published As

Publication number Publication date
IL162404A0 (en) 2005-11-20
PL371261A1 (en) 2005-06-13
ZA200406547B (en) 2006-06-24
CA2469721A1 (en) 2003-07-31
EP1465664A1 (en) 2004-10-13
CN1617745A (zh) 2005-05-18
PE20030851A1 (es) 2004-01-01
NO20043418L (no) 2004-08-17
KR20040077878A (ko) 2004-09-07
WO2003061708A1 (en) 2003-07-31
RU2004125283A (ru) 2005-06-10
JP2005515245A (ja) 2005-05-26
UY27614A1 (es) 2003-08-29
MXPA04006995A (es) 2005-07-13
TW200307750A (en) 2003-12-16
AR038153A1 (es) 2004-12-29
US20030232018A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
BR0306925A (pt) Formulações estabilizadas de adenovìrus
BRPI0412824A (pt) composições radiofarmacêuticas estáveis e métodos para suas preparações
BR0010555A (pt) Inibidores de neuraminidases
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
MA27551A1 (fr) Composition immunogene
BR0206955A (pt) Ligantes de receptores de canabinóides
EA200000703A1 (ru) Сульфонамидные производные в качестве пролекарств, ингибиторов аспартилпротеаз
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
DK0639577T3 (da) Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler
ES2157964T3 (es) Procedimiento de estabilizacion de vesiculas de lipido(s) anfifilo(s) y composicion para aplicacion topica que contiene dichas vesiculas estabilizadas.
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
NO933482D0 (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer
NO981628D0 (no) (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer
ATE360000T1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
EA200200147A1 (ru) Фармацевтическая композиция, содержащая фенофибрат, и способ ее получения
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BRPI0312173B8 (pt) vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
BR9808396A (pt) Processo para aumentar a deposição de um agente benéfico de uma composição em barra, e, barra
BRPI0515958A (pt) composição agroquìmica contendo éster de ácido fosfórico
ES2109735T3 (es) Composiciones adhesivas activables por humedad.
DK1089968T3 (da) Thyroideahormonanaloger og fremgangsmåder til deres fremstilling
BRPI0608430A2 (pt) composição adjuvante, processo para preparar a mesma e uso da mesma

Legal Events

Date Code Title Description
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]